HSD17B12 and neuroblastoma: This pediatric cancer has a complex molecular pathophysiology that includes genetic changes such as MYCN amplification, segmental chromosomal changes, and gene expression profiling.[8] Newer research has also revealed important genetic markers linked to low-risk forms of neuroblastoma, including anaplastic lymphoma kinase gene (ALK) mutations and genomic variants in genes including DUSP12, DDX4, IL21RA, and HSD17B12.[9] The oncogenesis of neuroblastoma has also been linked to changes in microRNA expression and epigenetic perturbations.[8]